Login / Signup

Emerging drugs for hemophilia A: insights into phase II and III clinical trials.

Hande KizilocakGuy Aaron Young
Published in: Expert opinion on emerging drugs (2021)
Novel therapies are already changing the way that hemophilia A is managed, and as more new therapies get approved, there will be a revolution in the management of this serious condition. Clinicians will have both the opportunities as well as the challenges of incorporating such new technologies into clinical practice.
Keyphrases
  • phase ii
  • clinical trial
  • clinical practice
  • open label
  • phase iii
  • double blind
  • palliative care
  • placebo controlled
  • study protocol
  • drug induced